EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Photodynamic Therapy for Glioblastoma: Potential Application of TiO2 and ZnO Nanoparticles as Photosensitizers

Emma Ortiz-Islas, María Elena Manríquez-Ramírez iD, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez, Elizabeth Ruiz-Sanchez iD, Karla Carvajal-Aguilera, Victoria Campos-Peña iD

Pharmaceutics · 29.08.2025 · 17 (9) · 1132

DOI: 10.3390/pharmaceutics17091132 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.08.2025. Verfasst von Emma Ortiz-Islas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Neurofarmacología y Nanotecnología Molecular, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 1426…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 234 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ciencia de Frontera.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite aggressive current therapies against glioblastoma (GB), residual tumor cells may remain at the edge of the surgical cavity after resection. These cells can rapidly proliferate, giving rise to tumor recurrence in more aggressive and drug-resistant forms. As photodynamic therapy (PDT) has advanced, it has emerged as an option to treat this brain tumor. The oncological basis of PDT involves the selective accumulation of a photosensitizer (PS) in the tumor, followed by its activation with electromagnetic radiation to generate reactive oxygen species (ROS), which induce tumor cell death. Given that first- and second-generation PSs present significant limitations, including poor tumor selectivity, suboptimal biodistribution, limited absorption within the therapeutic window, and slow systemic clearance, research has progressed toward the development of third-generation PSs based on nanotechnology to optimize their therapeutic properties. This review addresses the types of tumor cell death induced by PDT, as well as the advancements of PS design, focusing on titanium dioxide (TiO2) and zinc oxide (ZnO) nanoparticles. These nanomaterials can be designed as carriers, encapsulating or conjugating conventional PSs, or act as PSs themselves, due to their favorable biocompatibility and intrinsic photoreactivity. Additionally, they can be functionalized with targeting ligands to achieve tumor-specific delivery, enhancing therapeutic selectivity while minimizing toxicity to healthy tissue. Overall, these nanotechnology-based PSs represent a versatile and promising therapeutic paradigm that warrants further investigation through basic research, supporting the development and potential clinical translation of a more precise and effective PDT-based intervention for glioblastoma, initially aimed at eliminating intra-surgical post-resection residual tumor cells.

Schlagwörter

Stichwörter der Autor:innen

glioblastomananoparticlesphotodynamic therapyphotosensitizerstitanium dioxidezinc oxide

Autor:innen und Institutionen

  • Laboratorio de Neurofarmacología y Nanotecnología Molecular, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Laboratorio de Investigación en Nanomateriales y Energías Limpias, ESIQIE-IPN, Instituto Politécnico Nacional, Lindavista 07700, Gustavo A. Madero CDMX, Mexico City 14269, Mexico.
  • Laboratorio de Neuroinmunoendocrinología, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Laboratorio de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Laboratorio de Nutrición Experimental, Instituto Nacional de Pediatria, Mexico City 04530, Mexico.
  • Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.

ORCID-Profile: María Elena Manríquez-Ramírez, Elizabeth Ruiz-Sanchez, Victoria Campos-Peña

Förderung

  • Ciencia de Frontera

Zitieren

APA

Ortiz-Islas, E., Manríquez-Ramírez, M. E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sanchez, E., Carvajal-Aguilera, K., & Campos-Peña, V. (2025). Photodynamic Therapy for Glioblastoma: Potential Application of TiO2 and ZnO Nanoparticles as Photosensitizers. Pharmaceutics, 17(9), 1132. https://doi.org/10.3390/pharmaceutics17091132

Vancouver

Ortiz-Islas E, Manríquez-Ramírez ME, Montes P, Rodríguez-Pérez CE, Ruiz-Sanchez E, Carvajal-Aguilera K, et al. Photodynamic Therapy for Glioblastoma: Potential Application of TiO2 and ZnO Nanoparticles as Photosensitizers. Pharmaceutics. 2025;17(9):1132. doi:10.3390/pharmaceutics17091132

BibTeX
@article{OrtizIslas2025,
  author = {Ortiz-Islas, Emma and Manríquez-Ramírez, María Elena and Montes, Pedro and Rodríguez-Pérez, Citlali Ekaterina and Ruiz-Sanchez, Elizabeth and Carvajal-Aguilera, Karla and Campos-Peña, Victoria},
  title = {Photodynamic Therapy for Glioblastoma: Potential Application of TiO2 and ZnO Nanoparticles as Photosensitizers},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1132},
  doi = {10.3390/pharmaceutics17091132}
}
Kostenlos starten →